chronic spontaneous urticarial

Showing 1 posts of 1 posts found.


Novartis’ Xolair shows strong retreatment efficacy at Phase 3 in chronic spontaneous urticaria

September 18, 2017
Research and Development, Sales and Marketing Novartis, Xolair, chronic spontaneous urticarial, pharma, pharmaceutical

Novartis has released new data demonstrating the efficacy of Xolair (omalizumab) in the treatment of chronic spontaneous urticaria (CSU), a …

Latest content